Nonalcoholic steatohepatitis: what we know in the new millennium.
about
Insulin resistance in development and progression of nonalcoholic fatty liver diseaseEpigenetic mechanisms underlying the link between non-alcoholic fatty liver diseases and nutritionThe effect of an aerobic exercise on serum level of liver enzymes and liver echogenicity in patients with non alcoholic fatty liver disease.Effect of non-alcoholic fatty liver disease on carotid artery intima-media thickness as a risk factor for atherosclerosis.Inflammatory mediators of hepatic steatosis.Liver enzyme alteration: a guide for clinicians.Clinical usefulness of biochemical markers of liver fibrosis in patients with nonalcoholic fatty liver disease.Markers of liver function and inflammatory cytokines modulation by aerobic versus resisted exercise training for nonalcoholic steatohepatitis patients.Hepatoprotective and antioxidant activities of extracts from Salvia-Nelumbinis naturalis against nonalcoholic steatohepatitis induced by methionine- and choline-deficient diet in mice.Ciprofloxacin suppresses bacterial overgrowth, increases fasting insulin but does not correct low acylated ghrelin concentration in non-alcoholic steatohepatitis.Female hepatology: favorable role of estrogen in chronic liver disease with hepatitis B virus infection.Alanine aminotransferase within reference range is associated with metabolic syndrome in middle-aged and elderly Chinese men and womenEndoplasmic reticulum stress and the unfolded protein response in nonalcoholic fatty liver disease.Potential risk factors for nonalcoholic steatohepatitis related to pancreatic secretions following pancreaticoduodenectomy.Experimental evidence for therapeutic potential of taurine in the treatment of nonalcoholic fatty liver disease.Hepatic steatosis in obese patients: clinical aspects and prognostic significance.Best practice in primary care pathology: review 5.Nonalcoholic Steatohepatitis: Involvement of the Telomerase and Proinflammatory Mediators.Iron overload and cofactors with special reference to alcohol, hepatitis C virus infection and steatosis/insulin resistance.Metabolic syndrome is directly associated with gamma glutamyl transpeptidase elevation in Japanese womenNon alcoholic fatty liver disease: a clinical approach and reviewExtract of a polyherbal formulation ameliorates experimental nonalcoholic steatohepatitis.The role of fatty acids in the development and progression of nonalcoholic fatty liver disease.Biochemical parameters response to weight loss in patients with non-alcoholic steatohepatitisDysregulation of systemic iron metabolism in alcoholic liver diseases.Effects of n-3 polyunsaturated fatty acids from seal oils on nonalcoholic fatty liver disease associated with hyperlipidemia.CEACAM1 loss links inflammation to insulin resistance in obesity and non-alcoholic steatohepatitis (NASH).Absorption, Distribution, Metabolism, and Excretion of [(14)C]-Volixibat in Healthy Men: Phase 1 Open-Label Study.Induction of liver steatosis and lipid droplet formation in ATF6alpha-knockout mice burdened with pharmacological endoplasmic reticulum stress.Development of Fibrosis in Nonalcoholic Steatosis through Combination of a Synthetic Diet Rich in Disaccharide and Low-Dose Lipopolysaccharides in the Livers of Zucker (fa/fa) Rats.Tumour necrosis factor related apoptosis inducing ligand (TRAIL) induces hepatic steatosis in viral hepatitis and after alcohol intake.Impact of liver diseases on the development of type 2 diabetes mellitus.Hepatic mitochondrial beta-oxidation in patients with nonalcoholic steatohepatitis assessed by 13C-octanoate breath test.Differential mechanism and prognostic impact of diabetes mellitus on patients with hepatocellular carcinoma undergoing surgical and nonsurgical treatment.The role of vitamin E and C therapy in NASH.A pilot study of orlistat treatment in obese, non-alcoholic steatohepatitis patients.High glucose stimulates hepatic stellate cells to proliferate and to produce collagen through free radical production and activation of mitogen-activated protein kinase.Preventive role of genistein in an experimental non-alcoholic steatohepatitis model.Elevated Liver Enzymes in Asymptomatic Patients - What Should I Do?
P2860
Q26748687-6FE4D9EB-58AB-413A-A67A-2DC28BDA37B0Q26822513-90A2E364-72E6-44AD-9647-81BC16F44ACAQ33596745-38AEBBD3-0584-4D33-9F89-DDB286B3846BQ33596784-4A0E80C7-2194-417D-91EF-C34B0FFF1EB3Q33734136-B13F30C1-F59D-455F-A2E9-A26DB693524FQ33759637-10A55080-5985-45C1-AB16-0FB0C559ABD3Q34382683-D0E4494E-9298-4867-B65D-B21DC4C87ED4Q34405598-FCCDEA59-33C0-4A50-9366-9BF195A7CF6DQ34551170-D761E507-0F2D-48BE-B3A7-337366A693AFQ34560068-1BB79DE8-F3EA-4586-A354-0A0F608F170DQ34606036-3E6E6F16-8073-4B7F-A98E-C2F0832F84C3Q34773457-A776C5AF-C5A3-42E3-AA7F-94624DDA4FBDQ35055531-08335F95-DAFF-46F3-8BA9-46A1A9A7C9FEQ35235978-F8447C30-70F2-4219-A097-633CD3A11D16Q35601541-010EAC89-BABA-4AF8-8704-419170273F39Q35669794-7CA938B1-0FBC-4151-A56A-CA9F2CE6D967Q35770421-5ED36FA3-8C60-4DF6-AC54-D01270414C9FQ35931023-6FED6533-6F6D-44C5-96BF-2377B60B1239Q36177903-03990049-5873-4C1B-B97A-6A57A1FC2319Q36474639-49412900-E333-41BA-8157-37FF80F9ABFAQ36475998-15F796E8-DE89-4DA7-A3F4-EE627FF9CCEEQ36803083-9A93D927-0F33-4555-9F0F-30F95E11E04FQ36905995-BF09B5E9-95A6-4048-B055-DCB7ABEE09B7Q37025294-DE1F5EEF-4F50-4E27-865B-D505C54D7865Q37108895-91837569-552B-4838-91BC-B632C41EFD1AQ37397018-8EB56411-B227-4A2D-AFAC-73BFDECF35F8Q37624585-6C3AA492-0A1C-478D-9329-4EB0980CDB9EQ38374046-D4F3E92E-03FA-4080-B506-CF09B67971F5Q42451739-84B2C23A-F986-4AA4-BE81-61CA8956D2CBQ42606179-709016EB-8191-4863-98BA-C056B36B8DD8Q43004119-31D80DAE-ABB7-4794-8989-B0D042437745Q43040569-DB1CB40B-CB36-4BF6-AE10-D850D034354EQ44627897-381A2CE7-ADA5-4929-ABDE-99EFCC2B0E30Q44932270-AAA49802-98C0-4D86-B14F-67669D38794FQ45031745-29DF5276-CEC3-4D13-94DE-C8DAAFBD210EQ45048368-5A2175DB-FFCA-451D-B87C-023BDDFC2576Q46702712-A0C53DB7-3CEE-484F-9B32-98C512DB889FQ46967671-A8B57694-CF19-45C8-AC9D-BCF7FD916BA1Q47156253-9B046A56-30F7-474C-8E3C-7B36412DF473
P2860
Nonalcoholic steatohepatitis: what we know in the new millennium.
description
2002 nî lūn-bûn
@nan
2002 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Nonalcoholic steatohepatitis: what we know in the new millennium.
@ast
Nonalcoholic steatohepatitis: what we know in the new millennium.
@en
Nonalcoholic steatohepatitis: what we know in the new millennium.
@nl
type
label
Nonalcoholic steatohepatitis: what we know in the new millennium.
@ast
Nonalcoholic steatohepatitis: what we know in the new millennium.
@en
Nonalcoholic steatohepatitis: what we know in the new millennium.
@nl
prefLabel
Nonalcoholic steatohepatitis: what we know in the new millennium.
@ast
Nonalcoholic steatohepatitis: what we know in the new millennium.
@en
Nonalcoholic steatohepatitis: what we know in the new millennium.
@nl
P2093
P2860
P1476
Nonalcoholic steatohepatitis: what we know in the new millennium.
@en
P2093
Kevin A Lang
Shailesh Kadakia
Stephen A Harrison
Steven Schenker
P2860
P304
P356
10.1111/J.1572-0241.2002.07069.X
P407
P577
2002-11-01T00:00:00Z